Xeris Pharmaceuticals (XERS) Rises on Strategic Licensing Agreement With Amgen for Tepezza Development

Xeris Pharmaceuticals, Inc. XERS, a Chicago-based specialty pharmaceutical company, experienced a notable increase in its stock value, with a surge of 16% following news of a transformative licensing deal with biopharmaceutical giant Amgen Inc. AMGN. This collaboration centers on the utilization of XERS's proprietary XeriJect technology by AMGN to develop a novel subcutaneous formulation of teprotumumab for the treatment of Thyroid Eye Disease (TED), a debilitating condition affecting the eyes of people with hyperthyroidism. The agreement has been met with optimism by investors, signaling a potential positive growth trajectory for XERS.'s innovative XeriJect platform.

The Intricacies of the Licensing Deal

Under the terms of the licensing arrangement, AMGN, a leader in the biopharmaceutical sector known for leveraging recombinant DNA technology in their medical advancements, has obtained the rights to deploy XERS's XeriJect technology. This collaboration is poised to harness XERS's formulation expertise to enhance the delivery of teprotumumab—a drug previously intravenously administered—facilitating a more convenient subcutaneous administration that could revolutionize the standard of care for TED patients.

Implications for the Involved Companies

While XERS basks in the immediate uplift from the deal, AMGN's long-standing reputation for innovation is poised to be further bolstered by this venture into novel drug delivery systems. Investors and industry spectators will no doubt keep a close eye on the unfolding partnership, as well as its potential implications for similar companies like ADMA Biologics, Inc. ADMA, focused on products treating immunodeficiencies and infectious diseases, and Puma Biotechnology, Inc. PBYI, which emphasizes developing cancer care improvements. Both ADMA and PBYI are part of the broader biopharmaceutical market, continually innovating to address complex medical conditions.

Xeris, Amgen, Stocks